|1.||Scherz, Avigdor: 12 articles (10/2013 - 05/2002)|
|2.||Wilson, Brian C: 11 articles (04/2009 - 10/2002)|
|3.||Salomon, Yoram: 9 articles (01/2010 - 05/2002)|
|4.||Trachtenberg, John: 5 articles (04/2009 - 01/2005)|
|5.||Weersink, Robert A: 5 articles (04/2009 - 01/2005)|
|6.||Chen, Qun: 5 articles (12/2007 - 10/2002)|
|7.||Huang, Zheng: 5 articles (12/2007 - 10/2002)|
|8.||Hetzel, Fred W: 5 articles (12/2007 - 10/2002)|
|9.||Haider, Masoom A: 4 articles (04/2009 - 08/2006)|
|10.||Bogaards, Arjen: 4 articles (04/2009 - 06/2005)|
|1.||Prostatic Neoplasms (Prostate Cancer)
12/01/2015 - "The clinical and basic research data available to date show much promise for WST-09, and WST-11 based VTP eventually joining the standard urologist's armamentarium against prostate cancer. "
04/01/2014 - "Re: TOOKAD ® soluble vascular-targeted photodynamic (VTP) therapy: determination of optimal treatment conditions and assessment of effects in patients with localised prostate cancer."
10/01/2013 - "Considering patients who received 4 mg/kg TOOKAD(®) Soluble and 200 J/cm light (unilateral), which are considered optimal treatment parameters, 38/46 (83%) patients had histopathology from the biopsies that was negative for prostate cancer at 6 months (95% CI 68.6-92.2%; P < 0.001). "
10/01/2013 - "To evaluate the safety and quality of life after TOOKAD(®) Soluble VTP treatment in patients with localised prostate cancer. "
10/01/2013 - "To evaluate the optimal treatment conditions and effects of TOOKAD(®) Soluble vascular-targeted photodynamic (VTP) therapy in patients with localised prostate cancer. "
10/01/2013 - "Considering patients who received 4 mg/kg TOOKAD(®) Soluble and 200 J/cm light (unilateral), the mean 7-day necrosis percentage was 88% (46 patients) with extraprostatic necrosis reported in 72% (33/46) of patients. "
06/01/2005 - "Tookad-PDT-induced lesions, in both normal and cancerous prostates, were characterized by marked hemorrhagic necrosis. "
01/01/2010 - "Here, we show that a single treatment session of Tookad-based vascular targeted photodynamic therapy (VTP) promotes permanent arrest of tumor blood supply by rapid occlusion of the tumor feeding arteries (FA) and draining veins (DV), leading to tumor necrosis and eradication within 24-48 h. "
08/01/2006 - "At 7 days after PDT, gadolinium DTPA contrast-enhanced MRI is superior to DWI and T2 imaging in assessing the boundary of Tookad PDT-induced tissue necrosis in the normal canine prostate."
05/10/2003 - "The TOOKAD-PDT protocol targets the tumor vasculature leading to inflammation, hypoxia, necrosis and tumor eradication. "
01/01/2010 - "Tookad-VTP selectively targets the tumor feeding and draining vessels. "
01/01/2010 - "Tookad-VTP led to prompt tumor FA vasodilatation (a mean volume increase of 70%) with a transient increase (60%) in blood-flow rate. "
01/01/2010 - "A mouse earlobe MADB106 tumor model was subjected to Tookad-VTP and monitored by three complementary, non-invasive online imaging techniques: Fluorescent intravital microscopy, Dynamic Light Scattering Imaging and photosensitized MRI. "
01/01/2010 - "Permanent occlusion of feeding arteries and draining veins in solid mouse tumors by vascular targeted photodynamic therapy (VTP) with Tookad."
06/01/2004 - "The light source was an infrared-A irradiator fitted with appropriate filters, so that the wavelengths applied (665-800 nm) included the absorption maximum of TOOKAD at 763 nm. Tumor volume was monitored for 90 days after treatment or until a target volume (3.5 ml) was reached. "
|4.||Phototoxic Dermatitis (Phototoxicity)
08/01/2003 - "We studied the endobronchial phototoxicity of a novel photosensitizer, WST 09 (Tookad). "
01/01/2005 - "The cutaneous phototoxicity of TOOKAD was assessed in normal rat and pig animal models and in patients in a Phase-I trial of TOOKAD-mediated photodynamic therapy (PDT) for recurrent prostate cancer. "
08/01/2003 - "Endobronchial phototoxicity of WST 09 (Tookad), a new fast-acting photosensitizer for photodynamic therapy: preclinical study in the pig."
07/01/2014 - "The oncological outcome of both the TOOKAD and HEMI study will be crucial for any form of FT for prostate carcinoma in Germany in the future. "
08/05/2008 - "A response rate of more than half for those patients receiving the highest light doses shows the clinical potential of TOOKAD-VTP to manage recurrence of prostatic carcinoma after EBRT."
07/01/2007 - "To prospectively evaluate the magnetic resonance (MR) imaging appearance of the prostate and periprostatic tissues after vascular targeted photodynamic therapy (VTP) with palladium-bacteriopheophorbide for locally recurrent carcinoma after external beam radiation therapy. "
11/01/2003 - "We show that, although P-glycoprotein-expressing human HT29/MDR colon carcinoma cells in culture are resistant to PDT with Pd-bacteriopheophorbide (TOOKAD), the same treatment induces tumor necrosis with equal efficacy (88% vs 82%) in HT29/MDR-derived xenografts and their wild type counterparts, respectively. "
|3.||Gadolinium DTPA (Magnevist)
|9.||Hydrogen Peroxide (Hydroperoxide)
|1.||Photochemotherapy (Photodynamic Therapy)
|3.||Prostatectomy (Retropubic Prostatectomy)
|4.||Heterologous Transplantation (Xenotransplantation)